U.S. pharma giant copyright scrapped two experimental weight loss products final calendar year—a the moment-day by day capsule, lotiglipron, because of elevated liver enzymes as well as a two times-each day pill, danuglipron, on account of strong side effects—but CEO Albert Bourla has reported the company is decided to “Participate in and gai